Abbott Laboratories 10-Qquarter ended 2026-09-30

Executive Summary

Abbott sells medical devices, diagnostic tests, branded medicines and nutrition products to healthcare providers, laboratories and consumers. Its direction is shifting toward devices and diagnostics: Exact Sciences adds cancer screening and testing, while a planned Nutrition separation would narrow the portfolio. This quarter showed acquisition-driven sales growth, continued glucose-monitoring adoption and a Nutrition recovery, but financing costs, acquisition accounting and legal settlements sharply reduced pretax earnings. Investors must distinguish the enlarged business’s sales contribution from its earnings contribution, which has yet to become material.

What's Happening in the Business

The ≈$20.6B Exact Sciences acquisition, completed on 3/23/2026, established Abbott in cancer diagnostics through Cologuard, Oncotype DX and Cancerguard. Abbott also launched SimpleScreen CRC, a blood-based colorectal cancer screening test. These additions broaden its diagnostic offering beyond laboratory and infectious-disease testing; integration and commercial execution now matter alongside product development.

In October, Abbott announced plans to distribute shares in an independent Nutrition company to shareholders, targeting completion by end-2027. The intended tax-free separation remains conditional on approvals. Nutrition recovered in Q3, but its nine-month decline reflected weaker adult nutrition and U.S. pediatric volumes. The U.S. launch of Similac 360 Total Care Made With Whole Milk adds a product initiative during this transition.

Device development continued with U.S. approvals for Libre Duo and TactiFlex Duo and European approvals for Libre Duo and Amulet 360. Devices remain Abbott’s largest business, although quarterly sales growth slowed relative to the nine-month pace.

Infant-formula litigation also materially affected the quarter. Abbott recorded an ≈$670M charge for agreements resolving the Gill case and claims involving ≈2,000 additional infants. Separately, it paid ≈$385M, plus attorneys’ fees and interest, to resolve government investigations and claims concerning U.S. powdered-formula manufacturing. These agreements were not admissions or findings of liability.

Key Financial Highlights

• Diagnostics: Cancer Diagnostics contributed $1.98B since acquisition, nearly all the segment’s nine-month sales increase. Core Laboratory grew 4.0% excluding currency, supported by Alinity, while Rapid and Molecular declined 5.4% on weaker respiratory-testing demand. Acquisition-adjusted pro forma company sales grew 6.6% in Q3, showing that reported growth substantially exceeded comparable-business growth.
• Devices: Nine-month continuous glucose monitoring sales reached $6.2B vs $5.6B, growing 8.3% excluding currency through U.S. and international adoption. Electrophysiology grew 14% excluding currency, while overall device growth slowed in Q3.
• Costs outside segments: Q3 segment operating earnings totaled $3.42B, but consolidated pretax earnings absorbed $841M of intangible amortization, $297M of net interest expense and $829M of other net costs, including acquisition costs and legal settlements. A purchase-accounting revision alone added ≈$100M of quarterly amortization; that is not an operating deterioration.
• Cash generation: Nine-month OCF was $5.5B vs ≈$6.2B, reduced by legal payments, inventory investment and acquisition-related equity-award settlements. After $1.40B of capital spending, calculated FCF was $4.10B, leaving less internally generated cash for debt reduction and shareholder distributions.

Risk Assessment

• Acquisition leverage and valuation: The debt-funded purchase raises financing costs before Exact Sciences contributes material net earnings; its preliminary allocation includes $16.0B of acquired intangibles and $8.9B of goodwill, exposing Abbott to amortization and potential impairment.
• Infant-formula litigation: The settlements do not eliminate remaining claims, and Abbott cannot reasonably estimate additional possible losses that could materially affect cash flow or results.
• Tax disputes: Abbott contests $1.05B of IRS assessments and a $413M Malaysian assessment, creating potential cash demands alongside acquisition financing.

No risk-factor section was found in this 10-Q. A 10-Q does not have to restate the risk factors in the annual report. Full list: the company's 10-Ks on SEC.

What to Watch

• Cancer diagnostics: Subsequent filings should show whether the acquired tests sustain growth and begin contributing material earnings, rather than merely enlarging revenue.
• Device adoption: Continued glucose-monitoring growth and commercialization of Libre Duo and TactiFlex Duo would support the core franchise; further slowing would weaken that support.
• Nutrition separation: Management targets end-2027. Approvals and sustained sales recovery would strengthen the standalone business; delays or renewed volume declines would complicate the transition.
• Cash and leverage: Improving OCF and lower long-term debt would demonstrate capacity to absorb the acquisition; continued settlement payments and weak cash generation would constrain that progress.

Not present in this filing: Item 3, Quantitative and Qualitative Disclosures About Market Risk; Part II Item 1A, Risk Factors.